MAIA Biotechnology Inc MAIA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
MAIA Biotechnology Achieves Patient Enrollment Milestones in Ongoing Phase 2 and Pivotal Phase 3 Clinical Trials in Non-Small Cell Lung Cancer
-
MAIA Biotechnology Expands Pivotal Phase 3 THIO-104 Non-Small Cell Lung Cancer Trial into Spain and Portugal
-
MAIA Biotechnology Reports Pivotal Phase 3 Clinical Trial Progress in Advanced Non-Small Cell Lung Cancer
-
MAIA Biotechnology Doses First U.S. Patient in Ongoing Phase 2 Non-Small Cell Lung Cancer Clinical Trial
-
MAIA Biotechnology Announces Open Market Purchases of Company Stock by Long-Standing Board Member and CEO
-
MAIA Biotechnology Delivers Oral and Poster Presentations Showcasing Next-Generation Telomere-Targeting Cancer Therapies at IRT 2026
Trading Information
- Previous Close Price
- $1.12
- Day Range
- $1.08–1.15
- 52-Week Range
- $0.87–3.19
- Bid/Ask
- $1.04 / $1.11
- Shares Outstanding
- 61.74M
- Market Cap
- $67.92M
- Volume/Avg
- 363,522 / 490,474
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of targeted immunotherapies for cancer, with an initial focus on non-small cell lung cancer (NSCLC), which represents the majority of lung cancer cases. Its asset, ateganosine (THIO, also known as 6-thio-dG or 6-thio-deoxyguanosine), is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The treatment approach involves administering THIO followed by the immune checkpoint inhibitor Libtayo (cemiplimab), which is manufactured and commercialized by Regeneron.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 13
- Website
- https://www.maiabiotech.com
Valuation
|
Metric
|
MAIA
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 3.24 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
MAIA
|
|---|---|
Quick Ratio | 4.41 |
Current Ratio | 4.51 |
Interest Coverage | — |
Quick Ratio
MAIA
Profitability
|
Metric
|
MAIA
|
|---|---|
Return on Assets (Normalized) | −129.20% |
Return on Equity (Normalized) | −226.85% |
Return on Invested Capital (Normalized) | −231.42% |
Return on Assets
MAIA
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|p!pS&!> | LOCK|Sx>&> | $127B | |||
| Moderna Inc
MRNA
| LOCK|SP@HZ# | LOCK|vcQ | $87B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|@hzq#p | LOCK|$X&L | $81B | |||
| argenx SE ADR
ARGX
| LOCK|@TvTVbr | LOCK|Zp@ | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|fS%G<kx | LOCK|^?T | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|zGwSszz | LOCK|YvqN> | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|wJ$&hP> | LOCK|c>lTJ | $27B | |||
| Incyte Corp
INCY
| LOCK|f!pw>^ | LOCK|G@Z | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|^FL<JK | LOCK|@rc | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|#>$WVBl | LOCK|ny | $14B |
United States